{"id":906961,"date":"2025-11-06T13:43:45","date_gmt":"2025-11-06T18:43:45","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-third-quarter-2025-financial-results-raises-2025-guidance\/"},"modified":"2025-11-06T13:43:45","modified_gmt":"2025-11-06T18:43:45","slug":"collegium-reports-third-quarter-2025-financial-results-raises-2025-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/collegium-reports-third-quarter-2025-financial-results-raises-2025-guidance\/","title":{"rendered":"Collegium Reports Third Quarter 2025 Financial Results; Raises 2025 Guidance"},"content":{"rendered":"
\n

\n \u2013 Generated Record Quarterly Net Revenue of $209.4 Million,<\/em>
\n Up 31% Year-over-Year \u2013 <\/em>\n <\/p>\n

\n \u2013 Generated Record Quarterly Jornay PM<\/em>
\n
\n \u00ae<\/em>
\n <\/sup>
\n Net Revenue of\u00a0$41.8 Million; <\/em>
\n
\n Grew Prescriptions by 20% Year-over-Year \u2013<\/em>\n <\/p>\n

\n \u2013 Generated Record Quarterly Pain Portfolio Net Revenue of\u00a0$167.6 Million, Up 11% Year-over-Year, with All Three Core Products Growing Year-over-Year \u2013<\/em>\n <\/p>\n

\n \u2013 Raised Full-Year 2025 Net Revenue Guidance to be in the Range of $775 to $785 Million and Adjusted EBITDA Guidance in the Range of $460 to $470 Million<\/em>
\n \u2013<\/em>\n <\/p>\n

\n \u2013 Ended Q3\u201925 with Cash,\u00a0Cash Equivalents and Marketable Securities\u00a0of\u00a0$285.9 Million \u2013<\/em>\n <\/p>\n

\n \u2013 Conference Call Scheduled for Today at 8:00 a.m. ET \u2013<\/em>\n <\/p>\n

STOUGHTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc.<\/a> (Nasdaq: COLL) today reported its financial results for the quarter ended September 30, 2025, and provided a business update.<\/p>\n

\u201cWe delivered another strong quarter of results driven by our portfolio of differentiated medicines and unwavering commitment to patients,\u201d said\u00a0Vikram Karnani, President and Chief Executive Officer. \u201cJornay PM prescription growth was further bolstered by the start of the back-to-school season, as both patients and healthcare providers increasingly recognize the unique benefits of Jornay PM. The outstanding performance of Jornay PM, along with sustained growth across our pain portfolio, has led us to raise our 2025 financial guidance. As we move into the fourth quarter and look ahead to 2026, we remain dedicated to supporting patients with serious medical conditions while driving shareholder value through strong commercial execution, strategic business development, and disciplined capital deployment.\u201d<\/p>\n

\u201cNet revenue and adjusted EBITDA reached record highs this quarter, driven by strong performance from Jornay PM and our pain portfolio. Net revenue grew 31% year-over-year, while adjusted EBITDA increased 27% over the same period. We also generated meaningful operating cash flows, further strengthening our financial position,\u201d said Colleen Tupper, Chief Financial Officer.\u00a0\u201cWe continue to execute our capital deployment strategy which balances rapidly paying down debt, opportunistically repurchasing shares, and actively evaluating opportunities to expand our portfolio through business development. We are on track to achieve our updated guidance, setting a solid foundation for continued growth in 2026.\u201d<\/p>\n

\n ADHD Business Highlights<\/strong>\n <\/p>\n